The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Anti-EGFR rechallenge therapy with or without trametinib in addition to panitumumab in advanced CRC
Christine Megerdichian Parseghian, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents findings from a Phase II trial (NCT03087071) assessing anti-EGFR rechallenge therapy with or without trametinib, a MEK inhibitor, in addition to panitumumab in advanced colorectal cancer. 59 patients were enrolled and placed in three different cohorts based on pre-treatment circulating tumor DNA (ctDNA) mutations. An overall response rate (ORR) and disease control rate (DCR) of 18% and 67% were observed in patients with no acquired resistance mutations, whereas there were no responses in patients with acquired resistance to EGFR inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
